On Jan. 9, 2024, Biogen and Eisai announced that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody ‘LEQEMBI’ (brand name in China, generic name: lecanemab-irmb) had been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. Preparations for launch within the second quarter of Eisai’s FY 2024 (July 1 – September 30, 2024) were underway.